Inspra Helps, Natrecor Useless for Heart Patients
By wchung | 18 Jun, 2026
There’s good news for millions of people with mild or moderate heart failure. Studies show that the Pfizer drug Inspra and an implanted device from Medtronic can boost survival and cut down on trips to the hospital.
However, another drug that has been used for nearly a decade, Johnson & Johnson’s Natrecor (NAY’-treh-kor), did little to help people with severe heart failure in a study aimed at resolving safety concerns. Doctors say the drug seems safe but does not markedly help shortness of breath or save lives.
The studies were presented Sunday at an American Heart Association conference in Chicago.
MARILYNN MARCHIONE, AP Medical Writer CHICAGO
© 2026 by Asian Media Group Inc.
Recent Articles
- Global Demand Surges for Anti-Drone Technology
- BYD Looks to Formula One for Fast Global Brand Expansion
- Europe's EV Sales Keep Growing As Fuel Costs Rise, Car Prices Fall
- SK Hynix Ships Samples of Next-Generation AI HBM Chips
- Apple to Raise Prices Due to Memory Chip Shortage
- Trump Scraps Four More Offshore Wind Leases with $765 Million Refund
- Oil Roundtrips, AI Booms, US Consumers Spend, Economists' Fed Outlooks Go Wild
- Trump Endorsee Loses in Georgia Governor's Primary Race
- BMW Shares Sink After Profit Warning Highlights China and Iran Risk
- AI Will Lead to Labour Shortages, Bezos Says at Paris Conference
